Carisoprodol/Meprobamate, Screen Only, Urine
Use
This assay is intended for pain management—specifically for detecting carisoprodol and its metabolite meprobamate in urine samples to support monitoring of therapeutic use in a pain management context. It is not intended for workplace testing and does not comply with state regulatory workplace testing programs.
Special Instructions
This assay is intended for pain management. It is not intended for workplace testing and does not comply with state regulatory workplace testing programs.
Limitations
Not provided.
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 58370-8
Result Turnaround Time
3-5 days
Related Documents
For more information, please review the documents below
Specimen
Urine
Volume
20 mL
Minimum Volume
Not provided
Container
Plastic urine container
Storage Instructions
Maintain specimen at room temperature. If arrival at lab will extend beyond seven days, refrigerate.
Other tests from different labs that may be relevant